The IRAK4 Knockout HT29 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal population derived from the HT29 human colorectal adenocarcinoma cell line, engineered to disrupt the IRAK4 gene. This polyclonal knockout model introduces loss-of-function mutations within the IRAK4 locus, creating a heterogeneous cell pool suitable for studying IRAK4-dependent signaling without clonal selection. As a polyclonal knockout resource, it retains population-level genetic diversity while enabling robust functional interrogation of IRAK4 in innate immune and inflammatory pathways.
The parental HT29 cell line is a widely characterized epithelial model of human colorectal adenocarcinoma, originally isolated from a primary tumor. HT29 cells exhibit an epithelial morphology and are extensively used to investigate intestinal epithelial biology, colorectal cancer pathogenesis, and host-microbe interactions. Their ability to respond to microbial ligands and cytokines makes them particularly relevant for dissecting innate immune signaling in the gastrointestinal context.
IRAK4 encodes a serine/threonine kinase that functions as an essential proximal mediator of Toll-like receptor (TLR) and interleukin-1 receptor (IL-1R) signaling. Upon receptor stimulation by ligands such as LPS, flagellin, or IL-1??, IRAK4 is recruited to MyD88 adaptor complexes, where it interacts with MyD88 and IRAK2, and phosphorylates IRAK1. This phosphorylation event triggers the assembly of a signalosome containing TRAF6, leading to activation of TAK1 and subsequent phosphorylation of the IKK complex and MAP kinases JNK and p38. Downstream of IRAK4, these cascades drive NF-??B nuclear translocation and transcriptional induction of proinflammatory cytokines, including TNF-?? and IL-6. Additionally, Pellino proteins modulate IRAK4 activity through ubiquitin-mediated regulation, further fine-tuning signal propagation.
In the context of HT29 colorectal cancer cells, IRAK4-dependent pathways contribute to inflammation-driven tumor progression and the tumor microenvironment. Abrogation of IRAK4 function disrupts TLR/IL-1R responses, attenuating NF-??B and MAPK activation, which are often constitutively upregulated in colorectal cancer. This knockout model therefore provides a valuable platform to dissect the role of innate immune signaling in epithelial-derived tumor cells, to evaluate the impact of IRAK4 deficiency on inflammatory cytokine production, and to model immunodeficient states predisposing to bacterial infections. The polyclonal nature of the edited population minimizes clonal artefacts, permitting physiologically relevant assessments of pathway inhibition.
Researchers can employ this IRAK4 knockout model in a wide array of experimental applications, including western blotting to assess phosphorylated IRAK1 and total IRAK4 levels, NF-??B luciferase reporter assays, cytokine ELISA for TNF-?? and IL-6 secretion, and RT-qPCR for inflammatory gene expression profiling. Furthermore, co-immunoprecipitation studies can examine IRAK4 interaction with MyD88, while flow cytometry enables phospho-NF-??B detection. Drug sensitivity testing with IRAK4 kinase inhibitors and functional complementation assays reintroducing wild-type IRAK4 validate target specificity. These approaches support investigations into TLR/IL-1R signaling mechanisms, innate immunity, and colorectal cancer inflammation. For additional technical information or ordering, please contact Ascent Research.
